BaselDel-desiran failed a pivotal muscle disease trial.

Myotonic dystrophy still has no approved disease-modifying treatment for patients.

The Phase 3 trial missed its goal of improving patients’ hand-opening speed versus placebo.

Novartis faces a patent cliff after its second trial failure this week.

How each outlet framed it
STAT
connects trial collapse to Novartis' patent-cliff vulnerability and acquisition strategy concerns, notes 10% stock drop

Sources: STAT